PhRMA submits comments to USPTO highlighting important role of patent system in medicine development

PhRMA responded to the U.S. Patent and Trademark Office’s (USPTO) request for comments regarding USPTO initiatives to ensure the robustness and reliability of patent rights.
Read More
Six ways I-MAK is lying about biopharma patents

The Arnold-Venture funded advocacy group Initiative for Medicines, Access & Knowledge, Inc. (or I-MAK) is on a global media tour, espousing their point of view on the patent system. Some experts and...
Read More
New report ignores benefits of patent system to innovation and patients

A recent report from the Initiative for Medicines, Access & Knowledge – known as I-MAK – highlights fundamental misunderstandings about America’s patent system and how it benefits patients and...
Read More
The dangers of expanding the TRIPS waiver

World Trade Organization (WTO) members, including the United States, are considering waiving commitments to honor certain intellectual property (IP) rights on COVID-19 treatments, following a harmful...
Read More
Patent policy changes proposed by USPTO and FDA would leave patients behind

Kathi Vidal, Director of the USPTO, and Robert M. Califf, FDA Commissioner, recently outlined several policy areas where they plan to collaborate on addressing drug pricing. PhRMA supports the goal...
Read More
The time is now to address Brazil’s notorious patent backlog

It has been widely acknowledged that long patent examination delays cripple innovation, hinder economies, impede job creation and frustrate the launch of new products. Increased patent review times...
Read More
Legislation threatens patent protections and future innovation

Recently introduced legislation, the “Restoring the America Invents Act (RAIA),” if enacted, would push the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office to grant more...
Read More
Patients and innovators lose if the government pursues ‘march-in’

The Biden Administration this summer issued an executive order that seems to endorse the use of “march-in” – when the government seizes patent rights from an innovator to let competitors use that...
Read More
IP Explained: How does the U.S. patent process work?

Have you ever used a Teflon-coated pan or hit a golf ball down the fairway? Had a friend or family member receive treatment with a new medication? All these products were developed because patents...
Read More
New polling shows Americans are sounding the alarm on the TRIPS IP waiver

Last week, the Biden administration announced support for a waiver of the World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, which could lead to...
Read More